Drug Topics published its most comprehensive analysis of PBM restructuring this week. The framing matters: the pharmacy benefits industry is undergoing a massive restructuring driven by a wave of government action designed to shift focus back to the patient. The regulatory pressure forces the market to move beyond “transparency” talk to actual pricing clarity, fair medication access, and cost-plus reimbursement structures. And the independent pharmacy owner who understands the three forces converging simultaneously is in the best strategic position the profession has offered in a decade.
The Three Forces Converging Simultaneously
Force 1: Federal legislative mandate. The 2026 Consolidated Appropriations Act, signed into law in February and covered extensively in this newsletter at the time, established the most significant PBM reform framework in federal law since the passage of Part D itself. The CAA requires PBMs to provide employer health plans with detailed, semiannual reports on net drug spending, rebates, and spread pricing arrangements. It introduces a robust any willing pharmacy provision, meaning PBMs cannot arbitrarily exclude a qualified pharmacy from their network for competitive reasons, a protection that did not exist in federal law until this year. It prohibits spread pricing across Medicaid programs and mandates bona fide service fees only.
Force 2: FTC enforcement action. The Federal Trade Commission’s December 2024 administrative complaint against Express Scripts and CVS Caremark named specific anti-competitive practices in how the largest PBMs manage formularies and pharmacy network access. FTC settlements in 2026 are establishing precedent that PBM practices previously characterized as standard industry behavior constitute unfair methods of competition under Section 5 of the FTC Act. These remedies align with the CAA’s legislative mandates and create a dual federal enforcement architecture: legislative prohibition backed by regulatory enforcement.
Force 3: State-level structural reform. Tennessee’s FAIR Rx Act, covered in depth in this newsletter’s Tennessee PBM lawsuit issue, prohibits PBMs from owning pharmacies in the state and requires divestiture by July 2028. Missouri and Arkansas have enacted comparable state-level protections. State laws increasingly mandate acquisition-cost reimbursement plus dispensing fees, curb ghost networks and patient steering, and pursue Medicaid fee-for-service approaches to limit spread pricing.
These three forces are not sequential or independent. They are converging simultaneously on the same industry structure, applying pressure from federal legislation, federal antitrust enforcement, and state statutory reform in parallel.
The Specific New Rights Independent Pharmacies Hold Right Now
The CAA’s any willing pharmacy provision is the most immediately actionable change for independent pharmacy owners, and it is also the provision most likely to be incompletely understood or unenforced due to PBM non-compliance.
The provision requires that PBMs apply the same standard terms and conditions to any pharmacy willing and able to meet those conditions. This means a PBM cannot exclude your pharmacy from a network simply because your inclusion would reduce volume or revenue flowing to its affiliated pharmacies. Exclusion for anti-competitive reasons is now explicitly prohibited under federal law.
The Sam Maddula interview covered in this newsletter’s any willing pharmacy issue documented precisely how this legal tool, applied strategically, enabled the growth of a pharmacy serving underserved communities to $300 million in revenue across 20 states. The provision has existed in some state laws for years. It is now federal law. The difference is enforcement infrastructure and geographic reach.
Simultaneously, Optum Rx and Cigna’s Evernorth, also covered in this newsletter’s cost-based reimbursement issue, have already voluntarily transitioned their network pharmacies to cost-based payment models, citing both regulatory pressure and market competition from cost-plus disruptors like Mark Cuban’s Cost-Plus Drugs. Those voluntary transitions are partly driven by the legal environment the CAA has created. The pharmacist who understands that environment can use it as leverage in both network enrollment conversations and reimbursement rate discussions.
The transparency reporting requirements create a second layer of enforcement infrastructure. When PBMs provide semiannual reports to employer health plans on net drug spending and rebate arrangements, employers will for the first time be able to compare what they pay their PBM against what their PBM reimburses pharmacies. The spread that has funded PBM economics for three decades will be visible to the buyer who has been paying it. That visibility produces buyer pressure that works in independent pharmacy’s favor.
Why Independent Pharmacy Is Better Positioned Than It Has Been in a Decade
The specific business advantages the independent pharmacy model has always held, including patient relationships, clinical depth, community trust, and care coordination capability, have historically been undermined by a reimbursement system that did not compensate those advantages. The PBM model that captured most of pharmacy’s margin for three decades was built to reward volume, scale, and vertical integration, which structurally favored chains and PBM-affiliated pharmacies over independent operators.
The cost-plus, transparency-anchored system being built through the CAA and state-level reforms changes that structural dynamic specifically. In a cost-plus reimbursement environment, the dispensing fee is the margin driver. The independent pharmacy that buys smarter, negotiates better wholesaler relationships, and builds secondary sourcing options for high-volume generics keeps more margin than the one using a single wholesaler at standard pricing. That buying efficiency advantage is fully available to independents without the overhead and corporate governance constraints that limit chain pharmacy’s purchasing flexibility.
In a clinical services revenue environment, the independent pharmacy’s patient relationship depth is a genuine competitive advantage. The Shields-UMass diabetes coaching study, the NCPA Stroke Belt pilot, the Geisinger RPM program, and every other documented outcome study covered in this newsletter reached the same structural conclusion: pharmacist-led clinical programs that leverage longitudinal patient relationships produce better outcomes than programs that don’t. Independent pharmacies have those relationships. The reimbursement model being built now, through value-based care contracts, ACCESS Model coordination, and RPM billing, compensates those relationships directly.
In a transparency-required reimbursement environment, the independent pharmacy’s documentation capabilities become a competitive differentiator. The PBM that previously operated on information asymmetry, knowing exactly what it paid versus what it charged, while the pharmacy saw only the net payment, now operates in an environment where that asymmetry is legally prohibited. The independent pharmacy with good financial systems and documented intervention data is positioned to engage in network and reimbursement conversations from a more informed position than at any prior point in the PBM era.
The State Level Environment: Immediate Financial Reality
While the federal reforms establish the structural environment being built for 2029 and beyond, state-level reforms are the immediate financial environment that independent pharmacy owners can act on right now.
The Tennessee FAIR Rx Act, requiring CVS to divest its Tennessee pharmacy operations or restructure its integrated model by July 2028, is under federal court challenge but has not been enjoined during the litigation. Missouri and Arkansas have enacted comparable structural separation requirements that are similarly contested but similarly active.
More broadly, the state Medicaid fee-for-service reforms limiting spread pricing in Medicaid pharmacy claims are producing immediate financial changes in the highest-volume payer segment for many independent pharmacies. Medicaid managed care organizations that have been allowed to operate spread pricing arrangements are facing state audits and contract modifications requiring acquisition-cost reporting that mirrors the federal CAA’s transparency mandates.
The pharmacist who has mapped their payer mix by Medicaid versus commercial versus Medicare Part D exposure can identify which state-level reforms produce the most immediate margin impact in their specific practice and prioritize the compliance conversations and reimbursement negotiations accordingly.
The Competitive Dynamic with Chains and PBM-Affiliated Pharmacies
The restructuring environment is not uniformly beneficial for all pharmacy types. The independent pharmacy gains from any willing pharmacy provisions that prevent discriminatory network exclusion. The chain pharmacy affiliated with a vertically integrated PBM loses the preferential network position that vertical integration produced. The PBM-affiliated specialty pharmacy loses the formulary steering advantage that directed specialty drug volume to affiliated dispensers.
CVS Health’s lawsuit against Tennessee’s FAIR Rx Act, covered in this newsletter’s Tennessee issue, demonstrates precisely how high the financial stakes of this restructuring are for vertically integrated models. CVS’s warning that it would close all 134 Tennessee pharmacies rather than divest is not a bluff. It is a statement about the financial model: CVS’s pharmacy economics assume PBM-driven patient steering that the FAIR Rx Act explicitly prohibits.
When that steering advantage is removed, through state law, federal any willing pharmacy provisions, or both, the independent pharmacy competing for the same patient has a more level playing field than at any point in the past three decades. The patient who previously filled at CVS because their PBM steered them there is now a patient whose PBM cannot legally prevent them from choosing the independent pharmacy across the street.
Capturing that patient requires the independent pharmacy to be visible, clinically differentiated, and operationally ready. The market condition has improved. The pharmacy still must earn the business.
Your Enforcement Action This Week
The any willing pharmacy provision does not self-enforce. It creates a legal right that must be exercised through active communication with PBM representatives and, where necessary, through formal complaint processes with CMS and the FTC.
Contact your PBM representatives directly this week, specifically the representatives for the PBMs whose networks your pharmacy is not currently enrolled in or has been previously excluded from. Ask on the record: “What is your current timeline for compliance with the CAA’s any willing pharmacy provisions, and what documentation do we need to provide to ensure our pharmacy is included in networks we currently qualify for?”
Document the conversation. If the PBM cannot provide a specific compliance timeline or specific documentation requirements, follow up in writing. The written record of your attempt to enroll and the PBM’s response becomes the basis for a formal complaint if enrollment is denied without a legitimate, documented clinical or quality-based reason.
Your state pharmacy association is the most useful resource for identifying which PBM networks are active in your state, which have compliance gaps with the CAA’s any willing pharmacy provision, and whether any formal complaints or enforcement actions are currently underway. Several state associations have established PBM compliance reporting mechanisms specifically for this transition period.
The Sam Maddula pharmacist profile from this newsletter covered the practical strategy for using any willing pharmacy law as a business growth lever. The federal mandate that now exists provides stronger legal footing than the state-by-state landscape he navigated. The independent pharmacy owner who learns the provision’s specific requirements, enforces them systematically, and documents every network conversation from this point forward is operating in the legal environment the profession spent a decade advocating to create.
The PBM era is officially over. What comes next is being built right now. Build your position in it deliberately, before the transition period ends and the competitive dynamics of the new environment are fully established.
Sources: Drug Topics (Understanding the Restructure of US Pharmacy Benefits Amid Reform and Regulatory Action, August 2026), Drug Topics (How States and Federal Government Are Reforming PBM Practices for Pharmacy Viability, APhA 2026 Coverage), Buchanan Ingersoll and Rooney (Sweeping PBM Reforms Arrive: What the 2026 Federal Legislation Means for Pharmacies, Patients, and Employers), Drug Topics (The Consolidated Appropriations Act 2026 and PBM Reform: What Pharmacists Need to Know), Mintz Law (PBM Policy and Legislative Update, Spring 2026), American Journal of Managed Care (FAQs About New Legislation on PBM Reform, May 2026), Tennessee Lookout (CVS Sues Tennessee Over Pharmacy Benefit Manager Monopoly Law, May 2026), Drug Channels (Pharmacist Salaries and Employment in 2025, June 2026; Optum Rx and Cigna Cost-Based Reimbursement Transition Coverage), FTC Administrative Complaint (In the Matter of Caremark Rx LLC et al., PBM Insulin Formulary Practices, December 2024)